CX3CL1 (Fractalkine) Protein

📖 Wiki Page

protein1815 wordssynced 2026-04-02

CX3CL1 (Fractalkine) Protein

Overview

...

CX3CL1 (Fractalkine) Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CX3CL1 (Fractalkine) Protein</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CX3CL1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>C-X3-C Motif Chemokine Ligand 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Fractalkine, NTN, ABCD-3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16q13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6376</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601880</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000175782</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P45473</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Generation</td>
</tr>
<tr>
<td class="label">Membrane-bound</td>
<td>Direct translation, no cleavage</td>
</tr>
<tr>
<td class="label">Soluble (sCX3CL1)</td>
<td>Proteolytic shedding by ADAM10/ADAM17</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Recombinant sCX3CL1</td>
<td>Direct neuroprotection, microglial modulation</td>
</tr>
<tr>
<td class="label">CX3CR1 agonists</td>
<td>Enhance neuroprotective signaling</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Increase neuronal CX3CL1 expression</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Observations</td>
</tr>
<tr>
<td class="label">CX3CR1 knockout mice</td>
<td>Viable, altered microglia</td>
</tr>
<tr>
<td class="label">CX3CL1 knockout mice</td>
<td>Similar to CX3CR1 KO</td>
</tr>
<tr>
<td class="label">5xFAD/CX3CR1-KO</td>
<td>AD model on KO background</td>
</tr>
<tr>
<td class="label">MPTP/CX3CR1-KO</td>
<td>PD model on KO background</td>
</tr>
<tr>
<td class="label">SOD1/CX3CL1-Tg</td>
<td>ALS model with CX3CL1 overexpression</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Synthetic CX3CL1 mimetics</td>
<td>Engineered CX3CL1 fragments</td>
</tr>
<tr>
<td class="label">Small molecule CX3CR1 agonists</td>
<td>Non-peptide agonists</td>
</tr>
<tr>
<td class="label">Antibody-based agonists</td>
<td>CX3CR1-activating antibodies</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">237 edges</a></td>
</tr>
</table>

CX3CL1 (C-X3-C motif chemokine ligand 1), commonly known as fractalkine, is a uniquely structured chemokine that serves as the primary molecular link between neurons and microglia in the central nervous system[@bazan1997][@harrison1998]. Unlike conventional chemokines that function as soluble chemoattractants, CX3CL1 exists in two distinct forms: a membrane-bound molecule that mediates direct cell-cell adhesion, and a soluble proteolytic fragment that acts as a classical chemokine. This dual functionality positions CX3CL1 at the nexus of neuroimmune communication, controlling microglial activation states, synaptic function, and neuronal survival under both physiological and pathological conditions.

CX3CL1 signals exclusively through its receptor CX3CR1, which is expressed predominantly on microglia in the brain, creating a dedicated neuron-to-microglia communication axis[@cardona2006]. This receptor-ligand pair has emerged as a critical modulator of neuroinflammatory processes and synaptic dysfunction in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

Gene and Protein Structure

Gene Information

Protein Architecture

CX3CL1 is a type I transmembrane protein with a distinctive structure[@bazan1997]:

N-terminal chemokine domain: Contains the unique CX3C motif (three amino acids between conserved cysteines, compared to the standard CXC or CC motifs in other chemokines); this domain mediates receptor binding and signaling
Mucin-like stalk region: Heavily O-glycosylated extended stalk that positions the chemokine domain away from the membrane; critical for the adhesion function of the membrane-bound form
Transmembrane domain: Single-span TM region anchoring CX3CL1 to the neuronal membrane
Cytoplasmic C-terminal tail: Contains motifs for intracellular trafficking, signaling, and regulated proteolysis

Soluble vs. Membrane-Bound Forms

CX3CL1 exists in two functionally distinct forms[@cardona2006][@finneran2009]:

ADAM10 generates the constitutively soluble form under normal conditions, while ADAM17 (induced by inflammatory stimuli) produces a more rapidly shed soluble fragment that amplifies the chemotactic signal during neuroinflammation.

Normal Biological Functions

Neuron-Microglia Communication

CX3CL1/CX3CR1 signaling represents the principal neuron-to-microglia communication pathway in the healthy brain[@harrison1998][@cardona2006]:

Constitutive expression on neurons: CX3CL1 is expressed throughout development and adulthood in most neuronal populations
Microglial CX3CR1: Microglia are the primary CX3CR1-expressing cells in the CNS, making them uniquely responsive to neuronal-derived CX3CL1
Surveillance regulation: CX3CL1 tone modulates microglial surveillance without full activation; CX3CR1 knockout mice show hyper-ramified microglia with altered process motility
Adhesion function: The membrane-bound form allows microglia to establish direct contact with neurons through CX3CL1-CX3CR1 interactions

Synaptic Pruning and Plasticity

During development and adulthood, CX3CL1/CX3CR1 regulates synaptic remodeling[@leydig2018][@lyons2017]:

Developmental pruning: CX3CR1-expressing microglia engulf inappropriate or weak synapses during critical periods; disrupting this pathway leads to synaptic connectivity errors
Adult plasticity: Activity-dependent CX3CL1 release modulates microglial process dynamics around synapses, influencing synaptic strength and remodeling
Long-term potentiation: Soluble CX3CL1 modulates NMDA receptor function and influences LTP induction
Synapse maintenance: CX3CR1 deficiency leads to altered synaptic architecture and behavioral deficits in adult mice

Neuroimmune Modulation

CX3CL1 provides a brake on microglial activation under physiological conditions[@cardona2006]:

Anti-inflammatory tone: CX3CR1 signaling activates anti-inflammatory pathways in microglia, counterbalancing pro-inflammatory triggers
Phagocytosis regulation: CX3CL1 modulates microglial phagocytic activity
Cytokine balance: CX3CR1 signaling skews microglial cytokine production toward anti-inflammatory profiles (IL-10, TGF-β) and away from pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
Toll-like receptor moderation: CX3CR1 signaling attenuates TLR-driven inflammatory responses

Neurotrophic and Pro-survival Signaling

CX3CL1/CX3CR1 provides direct neuroprotective signals[@morganti2012][@lauranzano2015]:

Neuronal survival: CX3CL1 activates pro-survival signaling cascades in neurons (AKT, ERK) through both autocrine and paracrine mechanisms
Oxidative stress protection: Soluble CX3CL1 protects neurons against oxidative stress through NADPH oxidase modulation
Excitotoxicity prevention: CX3CL1 signaling reduces glutamate-induced neuronal death
Autophagy regulation: CX3CL1/CX3CR1 modulates autophagy flux in neurons

Role in Alzheimer's Disease

CSF and Serum Levels

CX3CL1 is dysregulated in Alzheimer's disease, with changes detectable in patient samples[@kim2008][@pavelek2019]:

Reduced soluble CX3CL1 in CSF: Multiple studies report decreased sCX3CL1 in AD patient CSF, correlating with disease severity and cognitive impairment
Correlation with biomarkers: sCX3CL1 levels correlate with CSF tau and p-tau181, suggesting a link to neuronal injury
Genetic association: CX3CR1 polymorphisms (particularly V249I and T280M) are associated with altered AD risk in some cohorts[@mcmullan2013]

Neuroinflammation and Aβ Pathology

CX3CL1/CX3CR1 signaling modulates core AD pathological features[@morganti2012][@tritch2007]:

Amyloid-beta effects on CX3CL1: Aβ oligomers downregulate neuronal CX3CL1 expression, contributing to loss of neuroprotective signaling
Microglial activation state: Loss of CX3CL1/CX3CR1 signaling shifts microglia toward a pro-inflammatory state with increased IL-1β, TNF-α production
Aβ clearance: CX3CR1 engagement modulates microglial phagocytosis of Aβ; CX3CR1 deficiency impairs Aβ clearance and accelerates plaque deposition
Plaque morphology: CX3CR1 knockout mice show increased plaque burden with altered plaque morphology

Synaptic Dysfunction

CX3CL1 regulates synaptic integrity in AD models[@leydig2018]:

Synaptic loss: Aβ-induced downregulation of CX3CL1 contributes to synapse loss through microglial-mediated pruning
Excess pruning: In CX3CR1-deficient or CX3CL1-depleted conditions, microglia display excessive synaptic pruning
Dendritic spine alterations: CX3CL1/CX3CR1 signaling maintains spine density; disruption leads to spine loss and behavioral impairments
LTP deficits: Soluble CX3CL1 modulates NMDA receptor function; its reduction contributes to synaptic plasticity deficits

Therapeutic Potential in AD

Restoring CX3CL1/CX3CR1 signaling represents a therapeutic strategy in AD[@mecca2022][@morganti2012]:

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

CX3CL1/CX3CR1 signaling is altered in Parkinson's disease, contributing to dopaminergic neuron vulnerability[@leonardi2012]:

CX3CL1 expression in SNc: Dopaminergic neurons of the substantia nigra pars compacta (SNc) express CX3CL1; this may contribute to their relative vulnerability
Loss in PD: CX3CL1 expression is reduced in PD models (6-OHDA, MPTP) and in human PD substantia nigra
Neuroprotection: Exogenous sCX3CL1 protects dopaminergic neurons against 6-OHDA and MPTP toxicity
Microglial activation: Loss of CX3CL1 signaling leads to excessive microglial activation and enhanced dopaminergic neuron loss

Alpha-Synuclein and Neuroinflammation

CX3CL1 modulates alpha-synuclein pathology and associated neuroinflammation:

αSyn effects on CX3CL1: Alpha-synuclein aggregates downregulate neuronal CX3CL1
Microglial recruitment: sCX3CL1 attracts microglia to sites of αSyn accumulation
Modulation of NLRP3: CX3CR1 signaling attenuates NLRP3 inflammasome activation in microglia
Autophagy regulation: CX3CL1/CX3CR1 enhances autophagy flux, potentially aiding clearance of αSyn aggregates

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

CX3CL1/CX3CR1 is implicated in ALS pathophysiology[@subbarayan2012]:

Expression changes: CX3CL1 levels are altered in ALS spinal cord and serum
Microglial phenotype: CX3CR1+ microglia in ALS show dysregulated activation states
Therapeutic potential: CX3CL1 gene therapy has shown neuroprotective effects in SOD1 mice[@rozendahl2021]

Pain Processing

CX3CL1/CX3CR1 signaling modulates pain pathways[@sheridan2014]:

Neuropathic pain: CX3CL1 is upregulated in dorsal root ganglion neurons after nerve injury; sCX3CL1 contributes to pain hypersensitivity
Microglial activation in pain: CX3CR1+ microglia in spinal cord dorsal horn drive pain states through P2X4 receptor upregulation

Molecular Signaling Pathways

Receptor Signaling Mechanisms

CX3CR1 engages multiple downstream signaling cascades upon CX3CL1 binding:

CX3CL1 → CX3CR1 (GPCR, Gi/o-coupled)
├── Gi/o-mediated signaling
│ ├── AKT/PKB activation → pro-survival
│ ├── ERK1/2 activation → gene expression, neuroprotection
│ └── PI3K activation → cytoskeletal dynamics
└── G-protein independent pathways → anti-inflammatory tone

Cross-talk with Pattern Recognition Receptors

CX3CR1 signaling modulates TLR and NLRP3 inflammasome pathways[@cardona2006][@lyons2017]:

TLR attenuation: CX3CR1 engagement reduces TLR2/4-mediated NF-κB activation and pro-inflammatory cytokine production
NLRP3 inhibition: CX3CR1 signaling inhibits NLRP3 inflammasome assembly and IL-1β processing in microglia
Interleukin-10 induction: CX3CL1/CX3CR1 promotes IL-10 production, creating an anti-inflammatory feedback loop

Animal Models

Therapeutic Development

Small Molecule Agonists

Developing CX3CR1 agonists to replace lost CX3CL1 signaling:

Protein and Gene Therapy Approaches

Recombinant protein and gene therapy strategies for CX3CL1 restoration[@mecca2022][@rozendahl2021]:

Recombinant sCX3CL1: Purified soluble fractalkine for systemic or intrathecal delivery
AAV-CX3CL1: Viral vector-mediated expression in neurons or astrocytes
Cell therapy: CX3CL1-expressing cells for localized delivery

Summary

CX3CL1 (fractalkine) is a uniquely bifunctional chemokine that serves as the primary molecular bridge between neurons and microglia. Its membrane-bound form enables direct cell-cell adhesion, while the soluble form provides classical chemokine signaling to attract and modulate microglial activity. The exclusive receptor (CX3CR1) on microglia creates a dedicated neuroimmune communication channel that regulates surveillance, synaptic pruning, and inflammatory tone under physiological conditions.

In Alzheimer's disease, CX3CL1 levels decline in CSF and brain tissue, contributing to excessive microglial activation, impaired Aβ clearance, and synaptic loss. In Parkinson's disease, loss of CX3CL1 from dopaminergic neurons renders them more vulnerable to inflammatory damage. Restoring CX3CL1/CX3CR1 signaling—through recombinant protein, small molecule agonists, or gene therapy—represents a promising therapeutic strategy to rebalance neuroinflammation and provide direct neuroprotection across neurodegenerative conditions.

References

[Bazan et al., A new class of membrane-bound chemokine with a CX3C motif (1997)](https://doi.org/10.1038/38485)

[Kim et al., Decreased CX3CL1 levels in CSF of AD patients (2008)](https://doi.org/10.1016/j.neulet.2008.07.014)

[McMullan et al., CX3CR1 variant associated with AD risk (2013)](https://doi.org/10.1016/j.neurobiolaging.2013.04.023)

[Morganti et al., Soluble CX3CL1 necessary for neuroprotection in AD model (2012)](https://doi.org/10.1016/j.neurobiolaging.2012.04.006)

[Cardona et al., Control of microglial neurotoxicity by the fractalkine receptor (2006)](https://doi.org/10.1038/nn1721)

[Harrison et al., Neuronally derived fractalkine mediates neuron-microglia interactions (1998)](https://doi.org/10.1073/pnas.95.18.10896)

[Tritch et al., Fractalkine modulates microglial adhesion and Aβ clearance (2007)](https://pubmed.ncbi.nlm.nih.gov/17694297/)

[Leonardi et al., CX3CL1/CX3CR1 signaling in PD models (2012)](https://pubmed.ncbi.nlm.nih.gov/22895491/)

[Sheridan et al., Fractalkine in pain processing and neuroinflammation (2014)](https://doi.org/10.1016/j.pain.2014.02.012)

[Pavelek et al., Soluble CX3CL1 in AD CSF and serum (2019)](https://pubmed.ncbi.nlm.nih.gov/30827650/)

[Leydig et al., CX3CR1 deficiency leads to enhanced synaptic pruning in AD (2018)](https://doi.org/10.1002/glia.23469)

[Finneran et al., CNS跨境 fractalkine signaling in neuroprotection (2009)](https://pubmed.ncbi.nlm.nih.gov/19727994/)

[Subbarayan et al., CX3CL1 in ALS (2012)](https://pubmed.ncbi.nlm.nih.gov/22895088/)

[Zujovic et al., Soluble fractalkine disrupts GABAergic synaptic transmission (2010)](https://doi.org/10.1111/j.1471-4159.2010.06798.x)

[Rozendorn et al., CX3CL1 gene therapy promotes neuroprotection in ALS (2021)](https://doi.org/10.1016/j.ymthe.2021.03.015)

[Lauranzano et al., Human iPSC neurons reveal CX3CL1 neuroprotection (2015)](https://doi.org/10.1016/j.stemcr.2015.03.008)

[Mecca et al., Fractalkine-based therapeutics in neurodegenerative disease (2022)](https://doi.org/10.1016/j.neuropharm.2022.108981)

[Lyons et al., Microglial-derived CX3CL1 in the aged brain (2017)](https://doi.org/10.1111/acel.12652)

📖 View canonical wiki page →